Charles River previews 2022: low-double-digit organic revenue growth, margin expansion, 9% capex

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Expects low-double-digit organic revenue growth in 2022 driven by sustained robust demand.
Non-GAAP operating margin improvement targeted towards ~22.5% by 2024.
Staffing levels increased ahead of plan; compensation expected to be headwind in 2022.
Capital expenditure guided at ~9% of total revenue in 2022, mainly for Safety Assessment capacity.
Outlook presented at Credit Suisse 30th Annual Healthcare Conference on Nov 9, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.